Cargando…

Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open‐label, 3‐arm parallel comparative, exploratory study

This study investigated the safety and efficacy of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor luseogliflozin with differing carbohydrate intakes in Japanese individuals with type 2 diabetes (T2D). Participants were randomly assigned to 3 carbohydrate‐adjusted meals for 14 days (days 1‐14;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yabe, Daisuke, Iwasaki, Masahiro, Kuwata, Hitoshi, Haraguchi, Takuya, Hamamoto, Yoshiyuki, Kurose, Takeshi, Sumita, Kiminobu, Yamazato, Hitoshi, Kanada, Shigeto, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412941/ https://www.ncbi.nlm.nih.gov/pubmed/27990776 http://dx.doi.org/10.1111/dom.12848

Ejemplares similares

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
por: Kuwata, Hitoshi, et al.
Publicado: (2017)

Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β‐cell function and the achievement of the glycated hemoglobin target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2017)

Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β‐cell function and the achievement of the HbA1c target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2018)

Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial
por: Kuwata, Hitoshi, et al.
Publicado: (2015)

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
por: Kuwata, Hitoshi, et al.
Publicado: (2021)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

The journey to understanding incretin systems: Theory, practice and more theory
por: Yabe, Daisuke, et al.
Publicado: (2019)

Mental distress and health‐related quality of life among type 1 and type 2 diabetes patients using self‐monitoring of blood glucose: A cross‐sectional questionnaire study in Japan
por: Tanaka, Nagaaki, et al.
Publicado: (2018)

Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
por: Kurose, Takeshi, et al.
Publicado: (2017)

Effects of physician’s diabetes self‐management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a self‐monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exploratory, open‐labeled, prospective randomized clinical trial
por: Tanaka, Nagaaki, et al.
Publicado: (2021)

Is caloric restriction enough to increase longevity? Fasting and circadian alignment
por: Hamamoto, Yoshiyuki, et al.
Publicado: (2023)

A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes
por: Kubota, Sodai, et al.
Publicado: (2020)

Retrospective analysis of safety and efficacy of insulin‐to‐liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β‐cell function
por: Usui, Ryota, et al.
Publicado: (2013)

Lifestyle changes as a result of COVID‐19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency
por: Tanaka, Nagaaki, et al.
Publicado: (2021)

Evaluation of skeletal muscle mass indices, assessed by bioelectrical impedance, as indicators of insulin resistance in patients with type 2 diabetes
por: Hirasawa, Yoshikazu, et al.
Publicado: (2019)

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2011)

Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels
por: Iwasaki, Masahiro, et al.
Publicado: (2012)

Stigma evaluation for diabetes and other chronic non‐communicable disease patients: Development, validation and clinical use of stigma scale – The Kanden Institute Stigma Scale
por: Tanaka, Nagaaki, et al.
Publicado: (2022)

Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs
por: Yabe, D, et al.
Publicado: (2015)

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan
por: Kubota, Sodai, et al.
Publicado: (2022)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
por: Usui, Ryota, et al.
Publicado: (2019)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
por: Seino, Hiroaki
Publicado: (2021)

Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin
por: Nakatani, Kaori, et al.
Publicado: (2012)

Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
por: Seino, Hiroaki
Publicado: (2021)

Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
por: Senmaru, Takafumi, et al.
Publicado: (2012)

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study
por: Seino, Yutaka, et al.
Publicado: (2017)

Exploratory analysis using machine learning of predictive factors for falls in type 2 diabetes
por: Suzuki, Yasuhiro, et al.
Publicado: (2022)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
por: Sawaki, Akira, et al.
Publicado: (2017)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

Generation of Angiotensin-Converting Enzyme 2/Transmembrane Protease Serine 2-Double-Positive Human Induced Pluripotent Stem Cell-Derived Spheroids for Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drug Evaluation
por: Higashi-Kuwata, Nobuyo, et al.
Publicado: (2022)

Add-On Effect of Angiotensin Receptor Blockade (Candesartan) on Clinical Remission in Active IgA Nephropathy Patients Treated with Steroid Pulse Therapy and Tonsillectomy: a Randomized, Parallel-Group Comparison Trial
por: Kohagura, Kentaro, et al.
Publicado: (2018)

Relationship and factors responsible for regulating fasting and post-challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus
por: Aoyama-Sasabe, Sae, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d0eaaeammqmfo5p9p7c7nadn71